[Table_StockNameRptType] 策略研究 月度报告 外部扰动与内部支撑的对决，波动加剧 [Table_RptDate] 报告日期： 2026-3-1 [Table_Author] 分析师：郑小霞 执业证书号：S0010520080007 电话：13391921291 邮箱：zhengxx@hazq.com 分析师：刘超 执业证书号：S0010520090001 电话：13269985073 邮箱：liuchao@hazq.com 分析师：张运智 执业证书号：S0010523070001 电话：13699270398 邮箱： zhangyz@hazq.com 分析师：陈博 执业证书号：S0010525070002 电话：18811134382 邮箱：chenbo@hazq.com 相关报告 1.策略月报《藏锋守拙—2026 年 2 月 A 股市场研判及配置机会》2026-02-01 2.策略月报《春风送暖—2026 年 1 月 A 股市场研判及配置机会》2026-01-04 3.策略季报《万境皆含春意—2026 年 一季度 A 股投资策略》2025-12-28 主要观点： 内需尚待提振。春节数 ...

[Table_StockName电Rpt力Typ设e] 备 行业周报 人形机器人惊艳亮相春晚，储能电芯集采涨价 行业评级： 增持 分析师：张志邦 执业证书号：S0010523120004 电话：15652947918 邮箱：zhangzhibang@hazq.com 执业证书号：S0010524050002 邮箱：liuqianlin@hazq.com 分析师：郑洋 执业证书号：S0010524110003 邮箱：zhengyang@hazq.com 执业证书号：S0010125040047 邮箱：caijinyang@hazq.com 求支撑明显 2026-01-22 2.北美缺电逻辑演绎，储能成为核心 解法 2026-01-22 东大储需求高增 2026-01-17 主要观点： 报告日期： 2026-02-27 储能：储能电芯集采价格上涨，阳光电源欧洲工厂落地 公司价格与沪深 300 走势比较 容量电价政策落地，储能后续需求支撑明显。碳酸锂价格上涨对储能 IRR 影 响较小。全球大储招标数据持续火热，国内储能反内卷推动储能高质量发展， 美国数据中心用电激增带动大储需求，欧洲户储需求温和复苏，大储成为主 要 ...

| 华安研究 2026年3月金股组合 | 归母净利润（百万元） | 归母净利润增速 | 营业收入（百万元） | 营业收入增速 | eps | pe(其余有说明) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 行业 | 金股代码 | 金股 | 核心推荐逻辑 | 风险提示 | 研究员 | 报告依据 | 2024A | 2025E | 2026E | 2024A | 2025E | 2026E | 2024A | 2025E | 2026E | 2024A | 2025E | 2026E | 2024A | 2025E | 2 ...

Investment Rating - The industry investment rating is upgraded to "Overweight" [3] Core Insights - The chemical industry is expected to experience a recovery driven by both cyclical and growth factors, with a focus on organic silicon, PTA, polyester filament, caprolactam, spandex, vitamins, sweeteners, refrigerants, and phosphorus chemicals [7] - The organic silicon industry is entering a recovery phase, with new applications becoming the core growth driver. From 2019 to 2024, domestic DMC capacity expanded rapidly, leading to temporary oversupply and declining prices. However, with no new capacity expected in 2025 and increasing demand from sectors like new energy vehicles and photovoltaics, the supply-demand balance is improving [7] - The PTA and polyester filament industries are approaching a turning point, with the expansion cycle nearing its end. The demand side is expected to continue growing, supported by easing trade tensions and improved external demand [7] - The introduction of quota policies is expected to lead refrigerants into a high prosperity cycle, with supply constraints and stable demand growth from markets like heat pumps and cold chain logistics [9] - The synthetic biology sector is poised for explosive growth, driven by the transition to low-energy products and breakthroughs in non-grain bio-based materials [9] - OLED technology is accelerating its penetration into various display sizes, supported by policy measures aimed at fostering the new display industry [10] - The demand for high-frequency and low-loss electronic resins is increasing due to the rise of AI infrastructure, with AI server shipments expected to grow significantly [11] - The electronic chemicals sector is benefiting from the expansion of wafer production capacity, with increasing demand for key materials like photoresists and packaging materials [12] Summary by Sections Industry Performance - The chemical sector's overall performance ranked 14th with a weekly change of 0.78%, outperforming the Shanghai Composite Index by 0.38 percentage points [6][21] - Key stocks such as Honghe Technology and Zhongcai Technology saw significant price increases due to rising demand in AI servers and high-speed network equipment [6] Supply-Side Tracking - A total of 155 companies in the chemical industry had their production capacities affected, with 4 new repairs and 7 restarts reported [14] Key Industry Dynamics - BlueStar announced the acquisition of Elkem's core organic silicon assets, marking a strategic move to enhance its position in the global organic silicon industry [34] - The first biofuel blending policy in China was approved, allowing for local blending and reducing reliance on imports [34]

Investment Rating - The industry investment rating is "Overweight" [2] Core Insights - The dye industry is expected to see a recovery in demand due to both domestic and international factors, with China maintaining its position as the world's largest producer, consumer, and exporter of dyes, with an annual production exceeding 900,000 tons [5][18] - The supply structure of dyes is improving, with leading companies possessing significant pricing power due to the elimination of smaller, less compliant enterprises [7][29] - The price increase of dyes is driven by the intermediate production process, benefiting companies with integrated supply chains [8][48] Summary by Sections Demand and Supply Dynamics - The dye industry is characterized by diverse products and applications, with significant growth in downstream printing and dyeing fabric production, which is projected to grow at a compound annual growth rate (CAGR) of 2.59% from 2018 to 2024 [20] - China's dye export volume is expected to reach 272,000 tons in 2024, reflecting an 11% year-on-year increase, supported by a compound annual growth rate of 7.51% from 2020 to 2025 [23] Environmental and Regulatory Landscape - The dye industry faces stringent environmental regulations, leading to the gradual elimination of high-pollution, low-compliance small enterprises, thus optimizing the industry structure [26][29] - Recent regulatory changes have increased compliance costs for smaller players, further consolidating market share among larger firms [30] Intermediate Supply and Price Trends - The production of key intermediates, such as H acid and reducing agents, is critical for dye manufacturing, with recent supply disruptions leading to price increases [40][45] - The price of reducing agents has surged from 25,000 yuan/ton to approximately 50,000 yuan/ton, directly impacting the production costs of disperse dyes [43] Key Companies in the Industry - Zhejiang Longsheng is a leading enterprise with a dye production capacity of 300,000 tons and a strong integrated supply chain [51] - RunTu Co. has a well-established dye industry system with a total dye production capacity of 238,000 tons [53] - Annoqi focuses on differentiated dye products and is integrating AI technology into its production processes [54] - Jinhua Group has a dye production capacity of 95,000 tons and is expanding its product portfolio through strategic acquisitions [56]

Investment Rating - The report does not explicitly provide an investment rating for the industry or funds analyzed Core Insights - The report introduces a new metric, portfolio skewness, to measure fund manager skill by analyzing the return distribution of U.S. mutual fund holdings, suggesting that higher skewness indicates better future performance [2][5] - The study finds that high-skewness funds significantly outperform low-skewness funds, with an annualized Fama-French-Carhart alpha difference of 2.88% before fees, translating to approximately $7.35 million annually [5][18] - The research indicates that portfolio skewness is a distinct predictor of fund performance, independent of existing skill metrics like active share and R² [5][39] Summary by Sections Introduction - The report discusses the importance of understanding mutual fund portfolio characteristics as they reflect fund manager skills and behaviors [15][21] Portfolio Skewness - Two skewness metrics are constructed: standard skewness (Pskew) and Pearson's second skewness coefficient (Pskew2), with the latter being more robust against extreme values [4][23] - The average portfolio skewness across the sample is positive, indicating a tendency for funds to hold more winning stocks [29][31] Sample Selection and Data Sources - The sample includes all U.S. actively managed equity funds from March 1980 to December 2023, with a total of 895,487 fund-month observations [27][28] Empirical Results Descriptive Statistics and Persistence of Skewness - The average Pskew is 0.265, with significant variability among funds, indicating that portfolio skewness is not randomly generated but reflects managerial behavior [29][32] Skewness and Future Fund Performance - High-skewness funds show a consistent performance advantage, with annualized alpha increasing by 0.444% for each quartile increase in skewness [40][43] - The report confirms a positive correlation between portfolio skewness and future fund performance, independent of common fund characteristics [42][44] Skewness and Other Skill Metrics - Portfolio skewness shows limited overlap with existing skill measures, suggesting it captures unique information about fund managers [46][48]

Investment Rating - Industry Rating: Overweight [1] Core Insights - On February 2, SpaceX announced the acquisition of Elon Musk's AI company xAI for $250 billion, based on a recent funding round of $20 billion. This acquisition aims to create "the most ambitious vertically integrated innovation engine on and off Earth" [3][13] - The acquisition reflects Musk's grand plan for building AI data centers in space, which could become a scalable development pathway for AI in the long term. SpaceX's CFO indicated that this transaction would not delay the planned IPO, which could raise up to $50 billion, valuing SpaceX at approximately $1.5 trillion [3][13] - SpaceX plans to launch a constellation of 1 million satellites to form an orbital data center, utilizing near-constant solar energy from space, which will significantly reduce operational costs. Musk estimates that launching 1 million tons of satellites, each generating 100 kW of computing power, will add 100 GW of AI computing capacity annually [4][14] - The integration of Musk's business empire, including rockets, AI, and social media platforms, is accelerating. This integration aims to create a closed-loop ecosystem, with a focus on space computing, commercial aerospace, and data centers. Relevant companies to watch include Cambricon, Zhongke Shuguang, and Yike Technology [5][15] Market Performance Review - The computer industry index fell by 3.27%, underperforming the Shanghai Composite Index by 2 percentage points and outperforming the ChiNext Index by 0.01 percentage points. Year-to-date, the computer industry index has risen by 3.44% [17][20] - Among the 31 industry indices, the computer industry ranked 27th this week, and it was second among the four TMT sectors (electronics, communications, computers, media) [17][20] Technology Software Industry News - The National Star Aerospace's Taizhou computing satellite innovation base has officially commenced operations, significantly enhancing the integration and deployment of computing satellite systems [26] - The low-altitude economy in China is entering an accelerated industrialization phase, with a goal to establish a standard system by 2027 [27] - Waymo completed a $16 billion financing round, becoming one of the largest single financings in the autonomous driving sector, with plans to expand its services globally [29][30] - A new network security framework has been developed to protect future 6G vehicle networks from quantum computing attacks, marking significant progress in quantum-safe mobile infrastructure [31][32] - The International Olympic Committee announced a partnership with Alibaba to create the first official AI model for the Olympics, showcasing the integration of AI technology in major international events [35][36]

Investment Rating - The investment rating for the company is "Buy" [1][10]. Core Insights - The surgical robot industry has a broad prospect with high clinical value, driven by both industry and policy [4][5]. - The domestic industry is at a pivotal moment, with increasing approval of domestic surgical robots and a growing number of local brands [4][5][6]. - The company is a leading player in the domestic surgical robot market, with a rich product portfolio and positive clinical feedback [7][8]. Summary by Sections Company Overview - The company, Shanghai MicroPort Medical Robotics, focuses on the design, development, and commercialization of surgical robots, aiming to assist surgeons in complex surgeries [17]. - Established in 2014, the company has developed a platform for innovation and industrialization in surgical robots, with multiple products approved for clinical use [18][20]. Market Potential - The global surgical robot market is expected to grow significantly, with a projected market size of $21.2 billion by 2024, reflecting a compound annual growth rate (CAGR) of 22.4% from $7.7 billion in 2019 [42]. - The laparoscopic surgical robot segment is the largest, accounting for over 50% of the total market [42]. Product Portfolio - The company has a diverse range of products, including the TUMAI laparoscopic surgical robot series and the Honghu orthopedic surgical robot series, with a total of seven commercialized products [8][20]. - The TUMAI series has been recognized in over 40 countries and regions, achieving significant sales and installations [8]. Financial Projections - Revenue is expected to reach RMB 569 million, RMB 896 million, and RMB 1.308 billion in 2025, 2026, and 2027, respectively, with year-on-year growth rates of 121%, 57%, and 46% [9][12]. - The company is projected to narrow its losses significantly, with a forecasted net profit of RMB 530 million by 2027 [9][12]. Competitive Landscape - The domestic market is seeing an increase in competition, with 11 local brands now approved for surgical robots, indicating a shift towards domestic alternatives to established international brands [5][53]. - The company maintains a competitive edge through its advanced technology and product offerings, which are well-received in both domestic and international markets [6][8].

Investment Rating - The industry rating is "Overweight" [3] Core Insights - The report highlights the ongoing active research in life sciences and the rapid integration of biotechnology into economic and social development, providing innovative solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy sector [3][4]. Industry Performance - The Huazhong Synthetic Biology Index increased by 0.11% to 1278.44 during the week of February 2-6, 2026, outperforming the Shanghai Composite Index by 1.39 percentage points and the ChiNext Index by 3.40 percentage points [4]. - The report notes that the synthetic biology sector is experiencing a policy dividend, with Shenzhen proposing up to 100 million yuan in support for R&D efforts in the field [8]. Company Developments - Beijing Huaguan Bio completed a multi-hundred million yuan C-round financing to enhance its R&D and production capabilities in the pharmaceutical and health sectors [32]. - Dejin Bio secured several million yuan in A-round financing to advance its recombinant botulinum toxin clinical research and international expansion [33]. - The report mentions that Impossible Foods is leveraging technology to reshape the plant protein market [11]. Market Dynamics - The report indicates that the synthetic biology sector is witnessing a surge in financing, with nearly a hundred companies completing new funding rounds since 2025 [31]. - The top five companies in the synthetic biology sector by stock performance during the week were Pingtan Development (+12%), Jinbo Bio (+12%), Huaxi Bio (+12%), Shandong Heda (+10%), and Yaxiang Co. (+10%) [17]. Policy and Regulatory Developments - The Ministry of Industry and Information Technology announced 35 examples of non-grain bio-based materials, marking a significant step towards establishing a new green development framework [7]. - The National Health Commission approved 22 new food items, including a significant breakthrough in domestic human milk oligosaccharides (HMOs) production [7]. Research and Innovation - Tsinghua University has initiated a national key R&D project focused on the intelligent design principles of efficient microbial chassis cells, aiming for breakthroughs in both fundamental theory and application demonstration [9]. - The report highlights the strategic cooperation between Tianjin University and China National Petroleum Corporation to expand efforts in synthetic biology and related fields [9].

Investment Rating - The industry investment rating is "Overweight" [3] Core Insights - The report highlights the ongoing active research in life sciences and the accelerating integration of biotechnology into economic and social development, providing new solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy sector [3][7]. Industry Performance - The Huazhong Synthetic Biology Index increased by 0.11% to 1278.44 during the week of February 2-6, 2026, outperforming the Shanghai Composite Index by 1.39 percentage points and the ChiNext Index by 3.40 percentage points [4][14]. - The report notes that the synthetic biology sector is experiencing a policy dividend, with Shenzhen proposing up to 100 million yuan in support for R&D efforts in the field [8]. Company Developments - Beijing Huaguan Bio completed a multi-hundred million yuan C-round financing to focus on new product development in the pharmaceutical and health sectors [31]. - Dejin Bio secured several million yuan in A-round financing to advance its recombinant botulinum toxin clinical research and international expansion [33]. - The report mentions that Impossible Foods is leveraging technology to drive market expansion and reshape plant-based protein [11]. Market Dynamics - The report indicates that the synthetic biology sector is witnessing a surge in financing, with nearly a hundred companies completing new rounds of financing since 2025 [31]. - The top five companies in the synthetic biology sector by stock performance during the week were Pingtan Development (+12%), Jinbo Bio (+12%), Huaxi Bio (+12%), Shandong Heda (+10%), and Yaxiang Co. (+10%) [17][21]. Policy and Regulatory Updates - The Ministry of Industry and Information Technology announced 35 examples of non-grain bio-based materials, marking a significant step towards building a new green development pattern [7]. - The National Health Commission approved 22 new food products, including a significant breakthrough in domestic human milk oligosaccharides (HMOs) technology [7]. Research and Innovation - Tsinghua University has initiated a national key R&D project focused on the intelligent design principles of efficient microbial chassis cells, aiming for breakthroughs in both fundamental theory and application demonstration [9]. - The report highlights the strategic cooperation between Tianjin University and China National Petroleum Corporation to expand in synthetic biology and other fields [9].